CSN Chesnara PLC

Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management

Hardman & Co Research
Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management

06-Jun-2023 / 10:30 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman Talks Video | Chesnara

Presentation and Q&A with Management

In this edition of Hardman Talks we were joined by the senior management of Surface Transforms, an established Life and Pensions Consolidator in the UK and Europe. Watch it here:

Chief Executive Steve Murray and Group Finance Director David Rimmington discuss Chesnara’s FY22 results and progress with analyst Brian Moretta.

After a presentation, we explore the results further, including looking at how new business is developing and how inflation is affecting the company. We also talk about the excellent cash generation in 2022, including some changes. Finally, we look at acquisitions, discussing prospects and capacity for future deals as well as the recently announced transaction with Canada Life.

Watch the recording:

Read more about the event here:

To be first in the know about Hardman & Co’s latest digital events, subscribe to the mailing list .

The Hardman Talks series is designed to share the latest sector insights and company investment cases from our corporate clients and our expert team of analysts. Click to subscribe to the Hardman Talks channel on YouTube.

Hardman & Co | 1 Frederick's Place | London | EC2R 8AE |

 

Hardman & Co Research can still be accessed for free after MiFID II.
Please to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1649781  06-Jun-2023 

fncls.ssp?fn=show_t_gif&application_id=1649781&application_name=news&site_id=research_pool
EN
06/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chesnara PLC

Brian Moretta ... (+3)
  • Brian Moretta
  • Jason Streets
  • Mark Thomas

Hardman & Co Monthly: May 2025

Feature article: Attractive asset managers - Radical derating presumes things only get worse The UK asset management sector has been significantly derated over the past couple of years. It has faced the dual problem of a shift towards passives and to private assets and away from traditional listed equities and bonds. However, the sector’s assets haven’t collapsed; its margins have proved relatively robust and its profits fairly stable, even against all the rising costs. The clear implication, ...

Brian Moretta
  • Brian Moretta

Chesnara plc (CSN): Showing good operational progress

Chesnara announced its 2024 results, which showed positive progress compared with 2023. The main features were positive market returns, offset by some mixed operational experience. Economic Value profit of £69.1m represented a 17% increase on the £59.1m in 2023. Economic Value increased to £531m, up slightly on £525m 12 months earlier, with a negative forex impact as well as dividend payment. Cash generation was excellent, with base cash increasing to £51.6m and commercial cash to £59.6m. The di...

 PRESS RELEASE

Hardman & Co research on Chesnara plc (CSN): Showing good operational ...

Hardman & Co Research Hardman & Co research on Chesnara plc (CSN): Showing good operational progress 07-Apr-2025 / 14:20 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Chesnara plc (CSN): Showing good operational progress   Chesnara announced its 2024 results, which showed positive progress compared with 2023. The main features were positive market returns, offset by some mixed operational experience. Economic Value profit of £69.1m represented a 17% increase on the £59.1m in 2023. Economic Value increased to £531m, up ...

Chesnara: 2 directors

Two Directors at Chesnara bought 25,695 shares at between 271p and 272p. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch